Abstract:Background & Aims: Prolactin (PRL) is a multifunctional polypeptide with effects on metabolism, however, little is known about its effect on hepatic steatosis and lipid metabolism. Herein, we aimed to assess the role of PRL in the development of non-alcoholic fatty liver disease (NAFLD). Methods: The serum PRL levels of 456 patients with NAFLD, 403 controls without NAFLD diagnosed by ultrasound, and 85 individuals with liver histology obtained during metabolic surgery (44 female and 30 male patients with NAFLD and 11 age-matched non-NAFLD female individuals) were evaluated. The expression of the gene encoding the prolactin receptor (PRLR) and signalling molecules involved in hepatic lipid metabolism were evaluated in human liver and HepG2 cells. The effects of overexpression of PRLR or fatty acid translocase (FAT)ICD36 or knockdown of PRLR on hepatic lipid metabolism were tested in free fatty acid (FFA)-treated HepG2 cells. Results: Circulating PRL levels were lower in individuals with ultrasound-diagnosed NAFLD (men: 7.9 [range, 5.9-10.3] mu g/L; women: 8.7 [range, 6.1-12.4]mu g/L) than those with non-NAFLD (men: 9.1 [range, 6.8-13.0] mu g/L, p = 0.002; women: 11.6 [range, 8.2-16.1] mu g/L, p <0.001). PRL levels in patients with biopsy-proven severe hepatic steatosis were lower compared with those with mild-to-moderate hepatic steatosis in both men (8.3 [range, 5.4-9.5] mu g/L vs. 9.7 [range, 7.1-12.3] mu g/L p = 0.031) and women (8.5 [range, 4.2-10.6] mu g/L vs. 9.8 [range, 8.2-15.7] mu g/L, p = 0.027). Furthermore, hepatic PRLR gene expression was significantly reduced in patients with NAFLD and negatively correlated with CD36 gene expression. In FFA-induced HepG2 cells, PRL treatment or PRLR overexpression significantly reduced the expression of CD36 and lipid content, effects that were abrogated after silencing of PRLR. Furthermore, overexpression of CD36 significantly reduced the PRL-mediated improvement in lipid content. Conclusions: Our results reveal a novel association between the central nervous system and the liver, whereby PRL/PRLR improved hepatic lipid accumulation via the CD36 pathway. Lay summary: Our clinical study suggests a negative association between prolactin (PRL)/prolactin receptor (PRLR) and the presence of non-alcoholic fatty liver disease (NAFLD). Using cell experiments, we found that PRL ameliorates hepatic steatosis via the hepatic PRLR and fatty acid translocase (FAT)/CD36, a key transporter of free fatty acid uptake in liver. Our findings suggest a novel approach to improving NAFLD using PRL and PRLR. (C) 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

PRLR regulates hepatic insulin sensitivity in mice via STAT5.

Central Prolactin Receptors (prlrs) Regulate Hepatic Insulin Sensitivity in Mice Via Signal Transducer and Activator of Transcription 5 (STAT5) and the Vagus Nerve

PRL/PRLR Can Promote Insulin Resistance by Activating the JAK2/STAT5 Signaling Pathway

Regulation Of Glucose Homeostasis And Lipid Metabolism By Ppp1r3g-Mediated Hepatic Glycogenesis

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

LRP1 facilitates hepatic glycogenesis by improving the insulin signaling pathway in HFD-fed mice

Prolactin Improves Hepatic Steatosis Via CD36 Pathway.

The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer

LRP6 Bidirectionally Regulates Insulin Sensitivity through Insulin Receptor and S6K Signaling in Rats with CG-IUGR

Beta-cell adaptation to metabolic stresses requires prolactin receptor signaling

Aberrant activation of liver X receptors impairs pancreatic beta cell function through upregulation of sterol regulatory element-binding protein 1c in mouse islets and rodent cell lines

PGC1α protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response.

Porcine reproductive and respiratory syndrome virus regulates lipid droplet accumulation in lipid metabolic pathways to promote viral replication

PGC1 protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response

Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet.

Liver-specific deletion of Ppp2c alpha enhances glucose metabolism and insulin sensitivity

Growth hormone receptor disrupts glucose homeostasis via promoting and stabilizing retinol binding protein 4

Low-Density Lipoprotein Receptor-Related Protein-1 Protects Against Hepatic Insulin Resistance and Hepatic Steatosis

LRG1 is an adipokine that mediates obesity-induced hepatosteatosis and insulin resistance

Liver-specific deletion of Ppp2cα enhances glucose metabolism and insulin sensitivity.

Reduction of Ptp1b by Rnai Upregulates the Activity of Insulin Controlled Fatty Acid Synthase Promoter